|
May 23
|
Ligand to Participate in Upcoming Investor Conferences
|
|
May 21
|
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
|
|
May 21
|
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
|
|
May 21
|
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
|
|
Apr 26
|
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
|
|
Apr 23
|
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
|
|
Feb 29
|
Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest?
|
|
Feb 28
|
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
|
|
Feb 28
|
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
|
|
Feb 28
|
Ligand Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
|
|
Feb 28
|
Q4 2023 Ligand Pharmaceuticals Inc Earnings Call
|
|
Feb 27
|
Ligand Pharmaceuticals Inc (LGND) Reports Solid Earnings Amidst Operational Transformation
|
|
Feb 27
|
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 11
|
Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights
|
|
Jan 11
|
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
|
|
Dec 27
|
13 Most Promising Small-Cap Stocks According to Analysts
|
|
Dec 8
|
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?
|
|
Dec 6
|
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
|
|
Dec 1
|
Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value Stock
|
|
Dec 1
|
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
|